Company plans to appoint Orlando D. Ashford as chairman
DUBLIN, November 8, 2021 / PRNewswire / – Perrigo Company plc (NYSE; TASE: PRGO), a leading supplier of Affordable Quality Personal Care Products, announced today that Rolf A. Classon, chairman of the board of directors of Perrigo Company plc, informed the board of directors that he intends not to represent himself on the board of directors of the company at its annual general meeting of shareholders in May 2022. Orlando D. Ashford, who joined the Company’s Board of Directors in december 2020, should be appointed as chairman of the board at the same meeting.
CEO and President of Perrigo Murray S. Kessler said, âOn behalf of the entire Board of Directors and management team, I would like to thank Rolf for his dedicated and effective service to the Company since 2017. He is an exceptional President and a remarkable leader. We are especially grateful for his leadership and contributions over the past three years as we have transformed Perrigo into a personal care company for consumers. “
Mr. Classon said: âI have tremendous optimism for the future of Perrigo, with its experienced and respected leaders on the board and management. It has been a pleasure to serve the company, the shareholders and be a part of the significant progress made at the Company. “
Mr. Classon, 76, has been a member of the Board of Directors since 2017 and was appointed Chairman in 2018. Mr. Classon’s decision not to stand for re-election is not the result of a disagreement with the Company, and he will continue in his chair until the annual general meeting of 2022.
Mr. Kessler continued, âOrlando will bring extensive and extensive experience to the role of President of Perrigo, having worked for a number of large consumer companies, including as a senior executive. I know Perrigo will continue to benefit from his guidance, ideas and tremendous leadership skills once he assumes the role of President following our next annual meeting. “
Mr. Ashford noted: âIt has been a privilege to be part of one of the most unique global personal care companies in the world. I look forward to continuing to work with Murray and my fellow Board members as we further strengthen Perrigo’s consumer profile and reputation for excellence. I too would like to thank Rolf for his leadership during my tenure. “
Perrigo Company plc (NYSE; TASE: PRGO) is a leading provider of quality, affordable personal care products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by enabling consumers to proactively prevent or treat ailments. which can be self-managed. Driven by its self-care strategy for consumers, Perrigo is the largest OTC store brand player in the United States in categories in which it competes with over 9,000 SKUs under customers’ own labels. Mark “. In addition, Perrigo is one of the top 10 over-the-counter companies in terms of turnover in Europe, where it markets more than 200 branded OTC products in 28 countries. Visit Perrigo online at www.perrigo.com.
Perrigo forward-looking statements
Certain statements contained in this press release are “forward-looking statements”. These statements relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or the achievements of the Company or its industry are materially different from those expressed or implied by forward-looking statements. In some cases, forward-looking statements may be identified by words such as “could”, “will”, “could”, “would”, “should”, “expect”, “expect”, “plan”, “” Intend “,” believe “,” estimate “,” predict “,” the potential “or the negative of these terms or any other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. Although the Company believes that these expectations, assumptions, estimates and projections are reasonable, these forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the control of the Company, including: the effect from the novel coronavirus (COVID-19) the pandemic and the associated supply chain impacts on the Company’s activities; general economic, credit and market conditions; future impairment charges; customer acceptance of new products; competition from other industry players, some of which have greater marketing resources or greater market shares in certain product categories than the Company; price pressures from customers and consumers; the resolution of uncertain tax positions, including the Company’s appeal against the draft and the final version of the Notice of Assessment Proposal (âNOPAâ) issued by the US Internal Revenue Service and the impact that ‘an unfavorable outcome of such a proceeding would have on operating results, cash flow, and liquidity; pending and potential third party claims and disputes, including disputes relating to the Company’s restatement of previously filed financial information and disputes relating to uncertain tax positions, including NOPAs; the potential impacts of ongoing or future government investigations and regulatory initiatives; the potential costs and reputational impact of product recalls or discontinued sales; the impact of tax reform legislation and health policy; the timing, amount and cost of any share buyback; fluctuations in exchange rates and interest rates; the Company’s ability to obtain the expected benefits from the sale of its Rx business and the risk that potential costs or liabilities incurred or retained in connection with the transaction may exceed the Company’s estimates or adversely affect the business or operations of the society ; the completion and success of the proposed acquisition of HRA and the ability to reap the expected benefits therefrom, including the risk that the parties may not obtain the required regulatory approvals or meet other conditions to close on time anticipated or not at all, the occurrence of any other event, change or circumstance which could delay the transaction or result in the termination of the contract for the sale of securities or the risk that the Company’s synergy estimates are inaccurate or that the Company makes facing integration costs or other costs higher than expected in the context of the acquisition project; the completion and success of other announced acquisitions or disposals, and the Company’s ability to derive the desired benefits; and the Company’s ability to execute and achieve desired benefits from advertised cost reduction efforts and strategic and other initiatives. An unfavorable outcome with respect to the Company’s appeal relating to significant outstanding tax assessments or pending litigation, including matters relating to securities or drug prices, may ultimately require the use of the assets of the Company. the business to pay such contributions, damages resulting from third party claims and interest and / or penalties, and such use of business assets would limit the assets available for other business purposes. These and other important factors, including those discussed under âRisk Factorsâ in the Company’s Form 10-K for the year ended December 31, 2020, as well as subsequent filings by the Company with the United States Securities and Exchange Commission, may result in actual results, performance or achievements materially different from those expressed or implied by such forward-looking statements. The forward-looking statements contained in this press release are made only as of the date hereof, and except as otherwise provided by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia: https://www.prnewswire.com/news-releases/rolf-a-classon-to-not-stand-for-re-election-as-chairman-of-the-perrigo -managers-board-301418488.html
SOURCE Perrigo Company plc